Drug name - Tyzeka
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7858594 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(11 months from now) | |
| US7589079 | NOVARTIS | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep, 2023
(11 months from now) | |
| CN1714098A | NOVARTIS | L-2 ' - Deoxythymidine Of Crystallized And Amorphous |
Aug, 2023
(10 months from now) | |
| CN100376593C | NOVARTIS | L-2 ' - Deoxythymidine Of Crystallized And Amorphous |
Aug, 2023
(10 months from now) | |
| EP1534727B1 | NOVARTIS | Pharmaceutical Compositions Of Crystalline Beta-L-2'-Deoxythymidine |
Aug, 2023
(10 months from now) | |
| EP1534727A4 | NOVARTIS | Crystalline And Amorphous Forms Of Beta-L-2 -Deoxythymidine |
Aug, 2023
(10 months from now) | |
| EP1534727A2 | NOVARTIS | Pharmaceutical Compositions Of Crystalline Beta-L-2'-Deoxythymidine |
Aug, 2023
(10 months from now) | |
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 100MG/5ML | SOLUTION;ORAL | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.